Kveim‑Siltzbach test (for sarcoidosis) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Kveim‑Siltzbach Test (Sarcoidosis) – Comprehensive Medical Guide

Kveim‑Siltzbach Test (for Sarcoidosis)

Overview

The Kveim‑Siltzbach test is a skin‑subcutaneous inoculation test historically used to support the diagnosis of sarcoidosis. The test involves injecting a small amount of standardized sarcoid tissue homogenate (the “Kveim” antigen) into the skin and observing the local immune response over several weeks. A positive reaction—a granulomatous nodule—is considered evidence of a cell‑mediated immune response typical of sarcoidosis.

Although the test has largely been replaced by more precise imaging (CT, PET) and laboratory markers, it remains a useful historical reference and is occasionally performed in research centers where the antigen is available.

  • Who it affects: Sarcoidosis can occur at any age, but the peak incidence is 20‑40 years. Women are slightly more often affected than men.
  • Prevalence: Worldwide prevalence ranges from 10–40 cases per 100,000 population, with higher rates among African‑American individuals (up to 60 cases/100,000) and people of Scandinavian descent.1

Symptoms

Sarcoidosis is a multisystem granulomatous disease; the Kveim‑Siltzbach test does not cause symptoms itself, but a positive test signals underlying disease. Common clinical manifestations include:

  • Respiratory: Dry cough, dyspnea on exertion, chest tightness, and especially bilateral hilar lymphadenopathy seen on chest X‑ray.
  • Skin: Erythema nodosum (tender red nodules on shins), lupus pernio (violaceous plaques on the nose and cheeks), and the Kveim nodule itself (granuloma at the injection site).
  • Eyes: Redness, photophobia, blurred vision, or uveitis, which can lead to cataracts or glaucoma if untreated.
  • Cardiac: Palpitations, heart block, or heart failure due to granulomatous infiltration of the myocardium.
  • Neurologic: Cranial nerve palsies, peripheral neuropathy, or seizures when the central nervous system is involved.
  • Musculoskeletal: Arthralgia, especially in the ankles, and myalgia.
  • General: Fatigue, low‑grade fever, weight loss, and night sweats.

Causes and Risk Factors

The exact cause of sarcoidosis remains unknown, but research suggests an exaggerated immune response to an unidentified antigen in genetically susceptible people.

Potential Triggers

  • Occupational exposures – e.g., beryllium, aluminum, or inorganic dusts.
  • Infectious agents – Mycobacteria, Propionibacterium acnes have been implicated in some studies.
  • Environmental factors – Rural living, exposure to agricultural dust.

Genetic Predisposition

Several HLA class II alleles (e.g., HLA‑DRB1*03) are associated with a higher risk of chronic disease, while HLA‑DRB1*14 is linked to a more benign course.2

Who Is at Higher Risk?

  • Age 20‑40 years (second and third decades).
  • African‑American and Scandinavian ancestry.
  • Family history of sarcoidosis or related autoimmune conditions.
  • Occupational exposure to inorganic particles.

Diagnosis

Because sarcoidosis mimics many other disorders, a combination of clinical, radiologic, histologic, and laboratory findings is required.

Step‑by‑step Diagnostic Approach

  1. Clinical assessment: Review of symptoms, physical exam for skin lesions, lymphadenopathy, eye involvement.
  2. Imaging:
    • Chest X‑ray – bilateral hilar lymphadenopathy is classic.
    • High‑resolution CT – evaluates parenchymal nodules, fibrosis, and mediastinal nodes.
    • FDG‑PET – useful for detecting active granulomas when the disease is extrapulmonary.
  3. Laboratory tests:
    • Serum angiotensin‑converting enzyme (ACE) – elevated in ~60 % of patients, but not specific.
    • Calcium levels – hypercalcemia occurs in 10‑20 % due to increased vitamin D activation.
    • Inflammatory markers (CRP, ESR) – often modestly raised.
  4. Histopathology: Tissue biopsy showing non‑caseating granulomas is the gold standard. Common sites: transbronchial lung, skin, lymph node, or muscle.
  5. Kveim‑Siltzbach test (optional):
    • Preparation – a homogenate of sarcoid tissue is mixed with sterile saline.
    • Procedure – 0.1 mL is injected intradermally into the forearm.
    • Interpretation – after 4–6 weeks, a firm, red‑brown nodule ≥5 mm indicates a positive test.
    • Limitations – variable sensitivity (30‑70 %), risk of transmitting infectious agents, and lack of standardization have limited its use.

Modern practice generally prefers biopsy and imaging; the Kveim test is reserved for centers with validated antigen preparations and when other methods are inconclusive.

Treatment Options

Treatment is individualized based on organ involvement, severity, and symptom burden. Many patients have self‑limited disease and need only observation.

When Treatment Is Recommended

  • Progressive pulmonary involvement (declining FVC or DLCO).
  • Cardiac or neurologic sarcoidosis.
  • Severe eye disease threatening vision.
  • Symptomatic hypercalcemia.

First‑Line Medications

  • Systemic glucocorticoids (prednisone 20‑40 mg/day, tapering over 6‑12 months) – mainstay for acute inflammation.3
  • Steroid‑sparing agents for long‑term control:
    • Methotrexate (10‑25 mg weekly) – most widely used.
    • Azathioprine (2‑2.5 mg/kg/day).
    • Mycophenolate mofetil (1‑1.5 g twice daily).

Second‑Line / Targeted Therapies

  • TNF‑α inhibitors (infliximab, adalimumab) – effective for refractory pulmonary, cutaneous, or neurologic disease.
  • Antimalarials (hydroxychloroquine) – useful for skin lesions and hypercalcemia.

Procedural Interventions

  • Bronchoscopy with transbronchial lung biopsy – both diagnostic and therapeutic for airway obstruction.
  • Implantable cardiac devices (pacemaker/ICD) for arrhythmias.
  • Eye surgery (cataract extraction, glaucoma filtration) when complications arise.

Lifestyle & Supportive Care

  • Smoking cessation – smoke exacerbates pulmonary fibrosis.
  • Vitamin D moderation and regular calcium monitoring.
  • Pulmonary rehabilitation for dyspnea and exercise intolerance.
  • Regular ophthalmologic exams (every 6‑12 months).

Living with Kveim‑Siltzbach Test (for Sarcoidosis)

A positive Kveim test signals that your immune system reacts strongly to sarcoid antigens. While the test itself does not alter daily life, the underlying disease may require ongoing management.

Practical Daily‑Management Tips

  • Medication adherence: Use a pill‑organizer, set alarms, and keep a medication list to avoid missed doses.
  • Symptom tracking: Record cough, shortness of breath, skin changes, and eye discomfort in a journal or app; share trends with your clinician.
  • Exercise: Aim for 150 minutes of moderate aerobic activity per week, adjusting intensity based on pulmonary function.
  • Nutrition: Balanced diet rich in fruits, vegetables, lean protein; limit high‑calcium foods if you have hypercalcemia.
  • Sun protection: If you are on hydroxychloroquine, avoid excessive sun to reduce photosensitivity.
  • Vaccinations: Stay up‑to‑date with influenza, COVID‑19, and pneumococcal vaccines (consult your doctor before live vaccines if on immunosuppressants).
  • Support networks: Join sarcoidosis patient groups (e.g., Sarcoidosis Foundation) for emotional support and up‑to‑date research.

Prevention

Because the exact trigger is unknown, primary prevention is challenging. However, risk reduction strategies include:

  • Minimizing occupational exposure to inorganic dusts (use respirators, adequate ventilation).
  • Maintaining good respiratory hygiene – avoid smoking and second‑hand smoke.
  • Prompt treatment of respiratory infections, which may act as a catalyst for immune activation.
  • Routine health screenings for high‑risk groups (African‑American adults 20‑40 years) to detect early disease.

Complications

If sarcoidosis remains untreated or poorly controlled, granulomatous inflammation can cause permanent organ damage.

  • Pulmonary fibrosis: Leads to irreversible loss of lung capacity and chronic respiratory failure.
  • Cardiac involvement: Heart block, ventricular arrhythmias, or heart failure, accounting for up to 25 % of sarcoidosis‑related deaths.4
  • Ocular complications: Glaucoma, cataracts, or permanent vision loss.
  • Neurologic sequelae: Facial nerve palsy, chronic meningitis, or seizures.
  • Hypercalcemia: Can cause kidney stones, nephrocalcinosis, or metabolic bone disease.
  • Psychosocial impact: Chronic fatigue and limited physical capacity may lead to depression and reduced quality of life.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden chest pain or pressure that radiates to the arm, jaw, or back.
  • Severe shortness of breath that does not improve with rest.
  • Palpitations accompanied by fainting, dizziness, or loss of consciousness.
  • Rapid vision loss, eye pain, or sudden swelling of the eye.
  • Acute neurological changes – sudden weakness, numbness, difficulty speaking, or seizures.
  • High fever (>38.5 °C/101.3 °F) with chills and worsening cough.

These symptoms may indicate life‑threatening cardiac, pulmonary, or neurologic involvement and require immediate evaluation.

References:

  1. Mayo Clinic. Sarcoidosis. Updated 2023. https://www.mayoclinic.org.
  2. New England Journal of Medicine. “Genetic susceptibility in sarcoidosis.” 2022;386:1345‑1355.
  3. Cleveland Clinic. Sarcoidosis Treatment Options. 2024. https://my.clevelandclinic.org.
  4. American Heart Association. “Cardiac sarcoidosis: clinical features and outcomes.” 2021. https://www.ahajournals.org.
  5. CDC. “Sarcoidosis – Data & Statistics.” 2023. https://www.cdc.gov.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References